Filing summary: AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX)
Entity and period: The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed March 15, 2021—not a Talphera, Inc. filing or a standalone 2020 Q4 report. The company-name and period metadata do not match the filing.
Business context
AcelRx develops and commercializes therapies for acute pain in medically supervised settings. Its principal commercial product is DSUVIA, a healthcare-professional-administered sublingual sufentanil tablet approved in the U.S. in 2018 and launched in 2019. DZUVEO is approved in Europe. Zalviso is approved and marketed in Europe, but its U.S. NDA has not been resubmitted following an FDA Complete Response Letter; timing depends partly on FDA opioid-approval guidance. ARX-02 and ARX-03 are inactive development programs.
Key financial metrics
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Total revenue | $5.416 million | $2.289 million |
| Product sales | $2.521 million | $1.830 million |
| Operating loss | $40.963 million | $54.205 million |
| Net loss | $40.379 million | $53.240 million |
| Net loss per share, basic and diluted | $0.47 | $0.67 |
| Net cash used in operating activities | $38.505 million | $51.180 million |
| Cash, cash equivalents and short-term investments at year-end | $42.886 million | $66.137 million |
DSUVIA sales were $1.409 million, up 274% year over year, primarily reflecting DoD purchases. Zalviso sales were $1.112 million, down 23%, as Grunenthal’s orders declined. Contract and other collaboration revenue rose to $2.895 million from $0.459 million, including $2.572 million recognized after Grunenthal’s termination eliminated certain deferred performance obligations.
Cost of goods sold was $6.032 million, exceeding total revenue by $0.616 million; this implies a negative gross result before operating expenses. Selling, general and administrative expense fell 19% to $36.330 million, and research and development expense fell 14% to $4.017 million. Interest expense was $3.305 million. The filing does not present a conventional gross-margin percentage that captures the mix of product and collaboration revenue.
At December 31, 2020, current assets were $46.830 million and current liabilities were $17.635 million. Oxford debt had an accrued balance of $21.0 million; scheduled maturity is June 1, 2023, and the loan is secured by substantially all assets other than intellectual property, subject to stated exceptions. A separate liability related to the sale of future royalties stood at $88.471 million, including $0.106 million current. The royalty liability is not ordinary bank debt, but its amount and amortization depend on future Zalviso royalties and milestones.
Material changes and unusual items
- Net loss narrowed by about $12.9 million year over year, while total revenue increased by about $3.1 million. SG&A reductions, lower R&D expense and non-cash royalty-related interest income contributed to the improvement.
- The royalty liability generated $3.310 million of non-cash interest income in 2020. The company says future amounts are uncertain after Grunenthal’s termination; a contingent gain of up to approximately $65 million may be recognized only if realized upon expiration of the liability.
- In March 2020, AcelRx eliminated 30 positions, mainly in commercial operations, and recorded $0.5 million of termination benefits. It reported approximately 25 sales representatives at year-end, including La Jolla’s team.
- Grunenthal terminated the Zalviso European collaboration, with sell-down rights extended through May 2021, when the territorial rights revert to AcelRx. AcelRx is obligated to use commercially reasonable efforts to negotiate a replacement license; none had been completed at filing.
- In 2020, the company raised approximately $21.3 million net through equity financings and ATM sales. After year-end, it raised approximately $28.9 million net in a public offering and $7.4 million net through the ATM.
Outlook, risks and contingencies
Management said existing capital resources were expected to fund operations for at least the next 12 months from the filing, but would not fund the company through the point at which revenue sustains operations. AcelRx expected significant losses in 2021 and identified additional capital as necessary for continued operations and commercialization. The company gave no specific revenue or earnings guidance.
- COVID-19 restrictions on access to healthcare facilities, delayed formulary reviews and reduced elective procedures constrained promotion and adoption of DSUVIA. Management expected near-term sales to remain affected while restrictions persisted.
- The high-volume automated packaging line was projected for installation in the first half of 2021, with FDA approval expected in 2022; timing had been delayed by COVID-19-related travel restrictions. Management expected the line to lower cost of goods sold in 2022 and beyond.
- DSUVIA received DoD Milestone C approval and was added to the Joint Deployment Formulary. A U.S. Army contract provided for up to $3.6 million over four years, but DoD orders may be irregular and are not assured.
- On February 11, 2021, the FDA issued a warning letter regarding promotional materials, citing allegedly misleading claims about DSUVIA risks and efficacy. AcelRx responded and sought clarification; it could not assure that FDA would be satisfied.
- Major risks include opioid-related regulation and potential litigation, DSUVIA’s restricted REMS distribution, single-source supply and manufacturing dependence, uncertain reimbursement and market acceptance, FDA uncertainty for Zalviso, and the need for financing. The Oxford loan requires at least $5.0 million of unrestricted cash and contains restrictive covenants.
Important facts for investors to verify
- Confirm the issuer: the filing is for AcelRx Pharmaceuticals, Inc. (ACRX), not Talphera, Inc.; confirm the intended reporting period is FY 2020 rather than Q4 alone.
- Review the audited financial statements and cash-flow runway assumptions, including the effect of post-year-end equity proceeds, ongoing cash burn and debt payments.
- Track DSUVIA sales, gross economics, customer concentration and the pace of hospital formulary approvals as COVID-19 restrictions ease.
- Check the resolution and any consequences of the FDA promotional warning letter, and the status, timing and requirements for any Zalviso NDA resubmission.
- Verify whether AcelRx secures a replacement Zalviso European partner before rights revert in May 2021, and how that affects the royalty-sale liability and any contingent gain.
- Monitor automated packaging-line installation and regulatory approval, as well as qualification of backup suppliers for key ingredients and components.